Multiple Ascending, Sequential, Placebo-controlled, Double-blind Study to Assess Safety, Tolerability and Efficacy of BVS857 in Severe Burn Subjects
Phase of Trial: Phase II
Latest Information Update: 11 Mar 2016
Price : $35 *
At a glance
- Drugs BVS 857 (Primary)
- Indications Burns
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 04 Mar 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 15 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 21 May 2014 Planned End Date changed from 1 Oct 2016 to 1 Sep 2016, as per ClinicalTrials.gov record.